This article is available in: PDF HTML EPUB XML

Currently available medications may not be sufficient for lifelong treatment of HIV

J Jansson, D Wilson, A Carr, K Petoumenos, M Boyd

Abstract


Purpose of the study: Combination antiretroviral therapy (cART) has greatly improved the life expectancy of people living with HIV (PLHIV). A series of cohort studies have predicted near-to-normal life expectancies for PLHIV receiving cART, but have not considered the impact of multi-class resistance on long-term survival. Our study aims to project the future life expectancy of PLHIV in a resource-rich setting in the context of the currently available antiretroviral treatments.

Methods: Patient antiretroviral treatment data, including time on each regimen until treatment failure, were sourced from an observational cohort of 3,434 predominantly male (94.2%) PLHIV in Australia over the period 1997-2010. These data were analysed in an individual-based mathematical model to calculate the time until exhaustion of all treatment options and the expected impact on HIV-associated mortality. Standardised mortality ratios were used to simulate expected survival before and after treatment exhaustion.

Summary of results: The model estimated that the median time until exhaustion of currently available treatment options is 43.4 years (IQR = 31.4-58.6 years). However, the model predicts that 10% of PLHIV will use up all currently available cART options after just 22.6 years. The figure shows the survival proportions of males from age 20 years in four mortality scenarios: (1) the general population mortality rate; (2) the mortality rate in PLHIV as currently measured (without considering exhaustion of currently available treatments); (3) mortality rate in PLHIV considering additional mortality due to limited cART options; and (4) mortality rate if no cART is available. PLHIV who start currently available cART regimens at age 20 years are expected to live to a median of 64.7 (95% uncertainty bound [UB] 61.8-69.3) years of age, when adjusting for treatment option exhaustion. This is a substantial improvement on no cART (median survival to 27.6 [95% UB 27.2-28.1] years of age), but is lower than the expected life expectancy (82.2 years of age) of an HIV-uninfected male in the general population. The gap between life expectancy among PLHIV and the general population is greater for those infected at younger ages.

Conclusions: As treatment options are exhausted in the coming years, a substantial difference in life expectancy between PLHIV and the general population is expected, particularly for people who acquire HIV at a younger age or who are currently highly treatment-experienced.

(Published: 11 November 2012)

Citation: Abstracts of the Eleventh International Congress on Drug Therapy in HIV Infection

Jansson J et al. Journal of the International AIDS Society 2012, 15(Suppl 4):18077

http://www.jiasociety.org/index.php/jias/article/view/18077 | http://dx.doi.org/10.7448/IAS.15.6.18077




Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.

Journal of the International AIDS Society | eISSN 1758-2652 | Editors-in-Chief: Susan Kippax, Kenneth Mayer and Papa Salif Sow 

*2016 Journal Citation Reports® Science Edition - a Clarivate Analytics product.

Disclaimer: The Journal of the International AIDS Society is an official journal of and is published by the International AIDS Society. The costs of the Journal of the International AIDS Society are secured by the International AIDS Society. This support does not in any way affect the editorial independency of the Journal of the International AIDS Society. Material published in the journal is entirely independent of the opinion of external sponsors and the society.